Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Biotechnology

Healthcare
$2.11 +1.84%

+$0.06 today

Market cap
$235.60M
Beta
0.47
P/E (TTM)
-1.7
EPS (TTM)
-$1.87
52W Low $2.40High $5.45

Volume 2.49M

Average 3.15M

RCKT Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Rocket Pharmaceuticals, Inc.NASDAQ: RCKT

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI remains negative

Q1 FY2026 Accumulated OCI was -$112K, compared with -$27K a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 1 of the last 3 fiscal years.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -314.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$112K-261.3% QoQ
Last fiscal yearDec 2025
-$31K-147.0% YoY
Year agoMar 2025
-$27K-314.8% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-314.8%——
1 year-147.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
(31K) USD
Year-over-year change
-147.0%

Accumulated OCI vs competitors

How RCKT compares with its peers on the latest reported figures

  • RCKT's Mar 2026 Accumulated OCI of -$112K is the 5th highest of the 10 companies compared; the peer median is -$207K.
  • Its year-over-year change of -314.8% is the 7th highest of 9, against a peer median of -74.3%.
  • Accumulated OCI amounts to 0.0% of total assets for RCKT, versus a peer median of 0.1%.
RCKT Competitors Peer median
Accumulated OCI for RCKT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
LBRXLB Pharmaceuticals Inc Common StockMar 2026$208K +1464788732394466.3%—0.1%
GALTGalectin Therapeutics Inc.Mar 2026$0 ——0.0%
SLDBSolid Biosciences Inc.Mar 2026-$13K -750.0%—0.0%
ANNXAnnexon, Inc.Mar 2026-$81K +11.0%—0.0%
RCKTRocket Pharmaceuticals, Inc.Mar 2026-$112K -314.8%—0.0%
AURAAura Biosciences, Inc.Mar 2026-$207K -297.1%—0.2%
DSGNDesign Therapeutics, Inc.Mar 2026-$268K -159.6%—0.1%
QSIQuantum-Si incorporatedMar 2026-$382K -19000.0%—0.2%
AUTLAutolus Therapeutics plcMar 2026-$6.63M +63.4%—1.3%
DBVTDBV Technologies S.A.Mar 2026-$9.9M +13.0%—3.7%
Peer median (excluding RCKT) -$207K-74.3%—0.1%

Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents232.69M140.52M55.9M163.64M77.56M
Short-term Investments156.05M215.88M317.27M208.7M111.37M
Net Receivables00000
Inventory00000
Other Current Assets07.67M5.05M5.85M3.81M
Total Current Assets392.06M364.06M378.22M378.18M192.73M
Property, Plant & Equipment (Net)72.35M77.65M87.59M83.32M71.59M
Goodwill30.82M39.15M39.15M39.15M39.15M
Intangible Assets025.72M25.15M25.15M25.15M
Long-term Investments043.28M34.32M01.34M
Tax Assets00000
Other Non-current Assets1.8M1.95M1.91M1.89M482K
Total Non-current Assets104.96M187.75M188.12M149.52M137.72M
Total Assets497.02M551.81M566.34M527.7M330.45M
Account Payables0001.63M0
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.53M10.01M9.93M185K12.29M
Total Current Liabilities22.17M39.17M48.51M40.68M30.21M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities80K2.6M2.94M1.14M1.06M
Total Non-current Liabilities20.13M22.95M25.26M23.78M23.02M
Total Liabilities42.3M62.12M73.77M64.47M53.23M
Common Stock645K791K903K1.07M1.08M
Retained Earnings(491.91M)(713.78M)(959.37M)(1.22B)(1.44B)
Accumulated OCI(161K)(357K)319K66K(31K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity454.72M489.69M492.57M463.23M277.22M
Total Debt22.6M22.87M25.04M25.5M24.88M
Net Debt(210.09M)(117.65M)(30.86M)(138.14M)(52.68M)

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Intrinsic Alpha fair value

Locked

Current Price

$2.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.